Clinical trials: Complication of Dialysis
Hemodialysis
STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE
We wanted to test the hypotheses that blood pressure level was lower, that the variability of blood pressure and blood glucose was reduced, and that quality of life was improved when glucose was added to the dialysis fluid.
- Trial name
- NCT00278057
- Testing
- dialysisis with and without glucose in the dialysis
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Regional Hospital Holstebro
Peritoneal Dialysis Complication, Sarcopenic Obesity
The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment
In this study, it was aimed to evaluate the effectiveness of medical nutrition therapy to be applied to patients with sarcopenic obesity receiving peritoneal dialysis treatment by measuring anthropometric measurements and blood…
- Trial name
- NCT05797181
- Testing
- medical nutrition therapy in kidney diseases
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Atlas University
Hyperphosphatemia, Chronic Kidney Disease
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
To evaluate the superiority to placebo, dose-responsibility and safety.
- Trial name
- NCT00505037
- Testing
- ASP1585, Sevelamer hydrochloride
- Where
- 6 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Inc
Hemodialysis Complication, Dialysis Access Malfunction
Six-month Response Rate According to Two Surgical Techniques (Rotational Atherectomy Versus Angioplasty) to Treat Stenosis of Vascular Accesses in Hemodialysis.
A well-functioning hemodialysis vascular access is a decisive factor in the survival of hemodialysis patients, who have a high mortality rate. 85% of these hemodialysis patients, are treated via an arteriovenous fistula (AVF).
- Conditions
- Hemodialysis Complication, Dialysis Access Malfunction, Stenosis
- Trial name
- ARSAV (NCT06868901)
- Testing
- Standard angioplasty + drug-eluting balloon technique, Atherectomy + drug-eluting balloon
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Anemia, Kidney Failure
Dynepo Infrequent Dosing Study
The purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of Dynepo in previously erythropoietin (EPO)-naive patients, as measured by haemoglobin at week 24 and…
- Trial name
- NCT00450333
- Testing
- Dynepo (Epoetin delta), Dynepo
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 407 people
- Sponsor
- Shire
Chronic Renal Failure, Chronic Kidney Disease
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- EMERALD 1 (NCT00597753)
- Testing
- peginesatide, Epoetin Alfa
- Where
- 89 sites in United States
- Volunteers
- 803 people
- Sponsor
- Affymax
Chronic Kidney Disease Stage 5, End Stage Renal Disease
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the…
- Trial name
- VIEWER (NCT05726526)
- Testing
- VIEWER virtual care platform
- Where
- 5 sites in Canada
- Volunteers
- 340 people
- Sponsor
- University of Manitoba
Chronic Kidney Disease, Chronic Renal Insufficiency
STAAR-3 Clinical Study
To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.
- Conditions
- Chronic Kidney Disease, Chronic Renal Insufficiency, Kidney Disease, Pre-dialysis
- Trial name
- NCT00369733
- Testing
- Darbepoetin alfa
- Volunteers
- 443 people
- Sponsor
- Amgen
Chronic Kidney Diseases, End Stage Renal Disease
The Effect of Exercise on Blood Parameters Related to Dialysis Patients' Survival
The purpose of this study is to check if patients' exercise during their dialysis sessions can improve the blood parameters which affect the heart disease and osteoporosis, so that we can help patients live longer.
- Conditions
- Chronic Kidney Diseases, End Stage Renal Disease, Hemodialysis
- Trial name
- NCT04916743
- Testing
- Intradialytic exercise group
- Where
- 2 sites in Iran
- Volunteers
- 44 people
- Sponsor
- Pardis Specialized Wellness Institute
Renal Anemia of Chronic Kidney Disease
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD)…
- Trial name
- NCT04885647
- Testing
- YPEG-rhEPO
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Kidney Diseases, Iron Deficiency Anemia
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney…
- Trial name
- COMPASS (NCT03236246)
- Testing
- KRX-0502
- Where
- 28 sites in United States
- Volunteers
- 206 people
- Sponsor
- Keryx Biopharmaceuticals
End Stage Renal Disease, Chronic Hepatitis c
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive…
- Trial name
- NCT04614142
- Testing
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Chronic Renal Disease
Application of Citrate Dialysate in Chronic Haemodialysis
Study investigating the safety and efficacy of the citrate dialysis solution compared to standard acetate dialysis solution. Use of citrate dialysis solution is not associated with a clinically relevant development of adverse…
- Trial name
- NCT01532297
- Testing
- Citrate dialysate (CiDi), Standard dialysate (StDi)
- Where
- 4 sites in Germany
- Volunteers
- 95 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
End Stage Renal Disease, Cardiac Insufficiency
Invasive Monitoring of Pulmonary Artery Pressure (PAP) Among Dialysis Treated Patients
The purpose of this study is examine whether invasive pulmonary artery pressure (PAP) monitoring could be beneficial for the patients in dialysis treatment.
- Trial name
- NCT02862197
- Where
- Finland
- Volunteers
- 8 people
- Sponsor
- Joint Authority for Päijät-Häme Social and Health Care
Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients
This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs)…
- Conditions
- Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury, Renal Dialysis, Critical Illness
- Trial name
- iCRRT (NCT07365111)
- Testing
- continuous renal replacement therapy
- Where
- Canada
- Volunteers
- 100,000 people
- Sponsor
- University of Alberta
Prevention of Thromboembolic Events
Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
BAY2433334 is under clinical development for prevention of complications in diseases such as heart attack, irregular heart beat or stroke which can arise by formation of blood clots elsewhere in the body and travels through the…
- Trial name
- NCT04510987
- Testing
- BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5, BAY2433334 on dialysis treatment day
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Bayer
Renal Insufficiency, Chronic, Inflammation
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
In this study 45 patients undergoing weekly dialysis for chronic end stage renal disease will be enrolled. The patients will be treated with a standard dialysis solution, containing acetate buffer, for 3 months; subsequently the…
- Trial name
- NCT03577249
- Testing
- Dialysis Solutions
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals
Chronic Kidney Disease (CKD) Stage 5
Effect of Pre-emptive Assessment of Self-care Peritoneal Dialysis (PD) Ability on PD Choice in Patients With Stage 5 Chronic Kidney Disease
Peritoneal dialysis is an effective renal replacement therapy with higher quality of life and lower treatment cost than hemodialysis.However, the application rate of peritoneal dialysis is much lower than that of hemodialysis.
- Trial name
- NCT04967547
- Testing
- Self-care PD ability assessment form, Education
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
CKD Anemia in Dialysis Participants
Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.
- Trial name
- NCT04059913
- Testing
- Roxadustat
- Where
- 25 sites in China
- Volunteers
- 318 people
- Sponsor
- Kyntra Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.